RecruitingNCT05319067

Study of Gut Microbiota Diversity in Children Aged 1-3 Years on Prolonged Antibiotic Prophylaxis for Grade 3 or Higher Vesicoureteral Reflux Compared With 2 Age-matched Control Groups


Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

150 participants

Start Date

Dec 2, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Urinary tract infections are very common in pediatrics. Urinary antibiotic prophylaxis is commonly used in children with malformative uropathies. Long-term, low-dose antibiotic prophylaxis with trimethoprim-sulfamethoxazole has been associated with a decrease in the number of urinary tract infections in susceptible children, but not systematically with a decrease in the risk of renal scarring (depending of uropathy stage). Long-term antibiotic prophylaxis has implications for the acquisition of antibiotic resistance. A child receiving antibiotic prophylaxis for urinary tract infection is around 6 times more likely to develop a multidrug-resistant infection. In the general population, the microbiota of children treated with curative antibiotics is less diverse in terms of species and strains. In addition, short-term compositional changes are observed between consecutive samples of children treated with antibiotics. The gut microbiota modulates the immune system, in particular via metabolites (SCFA, polysaccharide A) produced by bacteria that modify the expansion and function of regulatory T-cells. The disturbances of the intestinal microbiota play a role in the medium and long term on the acquisition of pathologies, such as atopy. The study authors wish to describe the intestinal microbiota of children with vesico-ureteral reflux treated long-term with trimethoprim-sulfamethoxazole and compared it those not receiving antibiotic prophylaxis and to healthy children.


Eligibility

Min Age: 1 YearMax Age: 3 Years

Inclusion Criteria7

  • The patient must be a member or beneficiary of a health insurance plan
  • Patient with no objection to participation in the study from the parent or guardian
  • Child with a diversified diet.
  • Child with grade 3 or higher vesicoureteral reflux.
  • Child on trimethoprim-sulfamethoxazole therapy for at least 5 months.
  • Child with uropathy and without long-term trimethoprim-sulfamethoxazole treatment.
  • Child without uropathy or long-term trimethoprim-sulfamethoxazole treatment.

Exclusion Criteria9

  • Chronic digestive pathology
  • Acute gastroenteritis or infectious colitis within last 15 days.
  • Curative antibiotic therapy taken less than one month ago.
  • Chronic inflammatory bowel disease or other localizations
  • Congenital or acquired immune deficiency (current treatment with methotrexate, biotherapies, immunosuppressants)
  • Patient participating in a category 1 trial likely to modify the intestinal microbiota.
  • Patient in an exclusion period determined by another study.
  • Patient under court protection, guardianship or curatorship.
  • Patient for whom it is impossible to give informed information to person with parental authority.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERStool sampling

Stool sample taken at home 24 hours before hospital visit


Locations(2)

CHU de Montpellier

Montpellier, France

CHU de Nîmes

Nîmes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05319067